VRTX
VERTEX PHARMACEUTICALS INC / MA
VERTEX PHARMACEUTICALS INC / MA (VRTX) Stock News
The latest VRTX headlines and market coverage — 1 recent story, updated throughout the day.
- Zacks Investment Research·
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?
Vertex Pharmaceuticals reported Q2 2026 earnings that missed EPS estimates ($4.73 vs $4.79 consensus) but beat revenue expectations ($3.33B vs $3.23B consensus). The company raised full-year 2026 revenue guidance to $13.10-$13.20B. However, analyst estimates have trended downward over the past month despite the stock gaining 14.4%. The company received a Zacks Rank #3 (Hold) rating with a VGM Score of D, suggesting in-line returns ahead.